Condition: Nephrectomy
Intervention: Procedure: Ambulant laparoscopic nephrectmy
Sponsors: University Hospital Roskilde; University Hospital Roskilde
Not yet recruiting - verified May 2012
Feeds
4628 items (4628 unread) in 80 feeds
Acinar Cell Carcinoma
(29 unread)
Acinic Cell Carcinoma
(33 unread)
Adenoid Cystic Carcinoma
(57 unread)
Adrenal Gland Cancer
(335 unread)
Ampulla Of Vater
(14 unread)
Anal Cancer
(252 unread)
Angiosarcoma
(73 unread)
Appendix Cancer
(35 unread)
Bile Duct Cancer
(386 unread)
Brain and CNS
(1151 unread)
Carcinoid
(143 unread)
Endocrine/Neuroendocrine
(291 unread)
Gall Bladder Cancer
(227 unread)
Hemangioendothelioma
(23 unread)
Hepatoblastoma
(31 unread)
Pancreas
(45 unread)
Phyllodes
(21 unread)
PMP and Mucinous Tumors
(19 unread)
Rhabdomyosarcoma
(191 unread)
Sarcoma
(602 unread)
Twitter Pals
(670 unread)
Trial - Appendix Cancer (7 unread)
-
Ambulant Laparoscopic Nephrectomy; Are There Limiting Factors
Posted: May 12th, 2012, 8:00am MDT
-
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix
Posted: April 17th, 2012, 8:00am MDT
Conditions: Carcinoma of the Appendix; Primary Peritoneal Cavity Cancer
Interventions: Drug: mitomycin C; Drug: oxaliplatin; Procedure: therapeutic conventional surgery; Other: quality-of-life assessment; Drug: hyperthermic intraperitoneal chemotherapy
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified October 2009 -
Cytoreduction Followed by Normothermic Versus Hyperthermic Intraperitoneal Intraoperative Chemoperfusion (HIPEC): a Study in Peritoneal Carcinomatosis
Posted: April 6th, 2012, 8:00am MDT
Condition: Peritoneal Carcinomatosis
Interventions: Procedure: Hyperthermic intraoperative Peritoneal Chemoperfusion; Procedure: Hyperthermic intraoperative Peritoneal Chemoperfusion; Drug: Hyperthermic intraoperative Peritoneal Chemoperfusion
Sponsors: University Hospital, Ghent; University Hospital, Ghent; University Ghent
Not yet recruiting - verified April 2012 -
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Posted: April 22nd, 2010, 8:00am MDT
Condition: Breast Cancer
Intervention: Drug: Temsirolimus plus Neratinib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Comprehensive Cancer Network; Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified May 2012 -
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
Posted: April 14th, 2010, 8:00am MDT
Condition: Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: Bendamustine and Ofatumumab
Sponsors: Teva Pharmaceutical Industries; Cephalon
Completed - verified April 2012 -
Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer
Posted: April 9th, 2007, 8:00am MDT
Conditions: Carcinoma of the Appendix; Colorectal Cancer; Primary Peritoneal Cavity Cancer
Intervention: Drug: oxaliplatin
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Completed - verified April 2012 -
UCN-01 and Irinotecan in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple-Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Posted: March 8th, 2002, 8:00am MST
Condition: Cancer
Interventions: Drug: 7-hydroxystaurosporine; Drug: irinotecan hydrochloride; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); University of Virginia; National Cancer Institute (NCI); Washington University Siteman Cancer Center
Completed - verified August 2009